Physician profile
David B Kugler
NPI 1174570147
$95,067.55
in general payments reported to CMS, 2019-2025
80 companies · $3,108 in 2025
The $3,108 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $20K · 2021: $19K · 2022: $3,468 · 2023: $3,490 · 2024: $3,555 · 2025: $3,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $37.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,115.67 |
| Education | $37.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $37,608.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $22,674.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $10,067.43 | 2019-2021 | |
| Abbvie INC. | $4,091.01 | 2019-2025 | |
| Novo Nordisk INC | $1,862.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,769.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,755.00 | 2019-2025 | Evenity, Repatha, Prolia |
| Xeris Pharmaceuticals, INC. | $1,221.74 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,182.79 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $1,049.93 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $803.15 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $762.97 | 2019-2025 | Korlym |
| Radius Health, INC. | $740.32 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $643.35 | 2019-2023 | |
| Ibsa Pharma INC. | $550.30 | 2019-2025 | Tirosint, Licart, Tirosint |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $548.25 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $519.30 | 2019-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $518.84 | 2022-2025 | |
| Abbott Laboratories | $453.10 | 2019-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $379.70 | 2019-2024 | Livalo, Seglentis |
| Antares Pharma, INC. | $363.70 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Tandem Diabetes Care, INC. | $318.79 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $294.42 | 2019-2022 | |
| Medtronic, INC. | $261.79 | 2021-2024 | Minimed 780g |
| Vivus LLC | $252.10 | 2019-2024 | Qsymia |
| Amryt Pharma Holdings LTD | $229.05 | 2022-2023 | Mycapssa |
| Lifescan, INC. | $216.60 | 2019-2023 | |
| Horizon Therapeutics Plc | $209.57 | 2019-2023 | Tepezza |
| Esperion Therapeutics, INC. | $199.51 | 2020-2025 | Nexletol |
| Cequr Corporation | $177.89 | 2022-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $175.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Alexion Pharmaceuticals, INC. | $174.85 | 2020-2025 | Strensiq |
| Becton, Dickinson and Company | $171.26 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $164.80 | 2019-2024 | Evkeeza |
| Recordati_rare_diseases_inc. | $151.86 | 2020-2025 | Signifor Lar, Isturisa |
| Ascendis Pharma Endocrinology INC | $148.07 | 2023-2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.01 | 2021-2024 | Cycloset, Cycloset |
| Eisai INC. | $136.52 | 2019 | |
| Mannkind Corporation | $127.54 | 2019-2024 | Afrezza |
| Shire North American Group INC | $121.93 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $117.69 | 2023-2024 | Baqsimi |
| Currax Pharmaceuticals LLC | $116.37 | 2020-2023 | Nexletol, Contrave, Nexlizet |
| Intuity Medical INC | $112.70 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Verity Pharmaceuticals INC. | $97.63 | 2024-2025 | Tlando |
| Pfizer INC. | $94.62 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $91.72 | 2020-2023 | Somatuline Depot |
| Aytu Biopharma, INC. | $89.56 | 2019-2020 | |
| Clarus Therapeutics INC. | $79.85 | 2021 | |
| Kyowa Kirin, INC. | $69.86 | 2024-2025 | Crysvita |
| Glycomark, INC. | $55.37 | 2019 | |
| Acella Pharmaceuticals, LLC | $54.27 | 2023-2025 | NP Thyroid 60 |
| Beta Bionics, INC. | $51.34 | 2024 | Ilet Bionic Pancreas |
| Chiesi USA, INC. | $50.75 | 2024-2025 | Mycapssa |
| Neurocrine Biosciences, INC. | $50.74 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $49.35 | 2021-2022 | |
| Medtronic Minimed, INC. | $43.00 | 2019 | |
| Embecta Corp. | $41.92 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Zealand Pharma US, INC. | $38.25 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $38.12 | 2021-2025 | |
| Halozyme INC | $36.18 | 2023 | |
| Althera Pharmaceuticals LLC | $34.87 | 2021 | |
| Azurity Pharmaceuticals, INC. | $34.19 | 2023 | Adthyza |
| Medicomp INC | $30.41 | 2025 | Telepatch Cardiac Monitor |
| Bigfoot Biomedical INC | $30.28 | 2022 | |
| Soleno Therapeutics, INC. | $28.04 | 2025 | Vykat Xr |
| Eusa Pharma (US) LLC | $25.27 | 2022 | |
| Endo Pharmaceuticals INC. | $24.83 | 2020-2021 | |
| Sandoz INC. | $23.20 | 2025 | Jubbonti |
| Almatica Pharma LLC | $21.70 | 2025 | Teriparatide |
| Sequel Med Tech, LLC | $21.20 | 2025 | Twiist |
| Avvisto Therapeutics, LLC | $19.65 | 2024 | Cycloset |
| Tolmar, INC. | $19.61 | 2025 | Jatenzo |
| Averitas Pharma INC. | $18.69 | 2023 | Qutenza |
| Rgh Enterprises LLC | $18.56 | 2025 | |
| Glaxosmithkline, LLC. | $17.68 | 2025 | Shingrix, Arexvy |
| G Medical Diagnostic Services, INC. | $17.62 | 2022 | |
| Companion Medical, INC. | $17.00 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $16.93 | 2025 | Imcivree |
| Valeritas, INC. | $15.83 | 2019 | |
| Alfasigma USA, INC. | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kugler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.